# Alnuctamab for Refractory SLE (LATTE Study)

> **NCT07219563** · PHASE1 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 21 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Alnuctamab

## Key facts

- **NCT ID:** NCT07219563
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07219563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07219563, "Alnuctamab for Refractory SLE (LATTE Study)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07219563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*